G. Rekhtman

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study

D. Esseltine, H. van de Velde, P. Moreau, 2015, Haematologica.

Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: An international multicenter randomized trial

T. Dolai, Sergey M. Alekseev, G. Rekhtman, 2019, Hematological oncology.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

D. Esseltine, H. van de Velde, P. Moreau, 2011, The Lancet. Oncology.

Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.

M. Hallek, A. Engert, B. Jakšić, 2011, The Lancet. Oncology.

A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma

P. Moreau, X. Leleu, T. Robak, 2010 .

Key Results of International Randomized Open-Label Clinical Study of BCD-020 (rituximab biosimilar candidate) in Patients with B-Cell Non-Hodgkin’s Lymphoma

S. Rajappa, S. Nirni, Z. Maslyak, 2014 .